ClinicalTrials.gg
CompletedNCT05581823Updated Apr 20, 2023

Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants

A Phase 1 interventional study of Tavapadon and Carbamazepine in Parkinson Disease, sponsored by Cerevel Therapeutics, LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-20.

Sponsored by Cerevel Therapeutics, LLC (part of AbbVie) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2023, 3 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing tavapadon in Parkinson Disease — none open to participants now, none under way, none of them phase 3. tavapadon · Parkinson Disease.

Enrollment
11th of 11
16 · median 57
Started
2022
with 1 other
Phase 1
5 of 11
none open now
Registered
10th of 11
by date
Lead sponsor
3 of 11
Cerevel Therapeutics, LLC

Among the 11 studies testing tavapadon in Parkinson Disease, this one is the 11th largest by enrollment, is one of 2 that started in 2022, is one of 5 in phase 1, and was the 10th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 11 studies testing tavapadon in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About tavapadon

tavapadon: first FDA approval 2026 (JUVMO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing tavapadon in Parkinson Disease as a file.
02

Study summary

The primary purpose of this study is to evaluate the effect of carbamazepine, a strong CYP3A4 inducer, on the steady-state pharmacokinetics (PK) of tavapadon in healthy adult participants.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women of nonchildbearing potential and men 18 to 55 years, inclusive, at the time of signing the form (ICF).
  2. Sexually active men with a pregnant or nonpregnant partner of must agree to use a condom during the trial and for 90 days after the last dose of carbamazepine. In addition, male participants should not donate sperm for a minimum of 90 days following the last dose of carbamazepine.
  3. Healthy as determined by medical evaluation, including medical and psychiatric history, physical and neurological examinations, , vital sign measurements, and laboratory test results, as evaluated by the investigator.
  4. of 18.5 to 32.0 kilograms per square meter (kg/m\^2), inclusive, and total body weight >50 kg (110 pounds [lbs]) at Screening.
  5. Capable of giving signed informed consent as described in the full protocol, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  6. Ability, in the opinion of the investigator, to understand the nature of the trial and comply with protocol requirements, including the prescribed dosage regimens, scheduled visits, laboratory tests, and other trial procedures.

Exclusion criteria

Exclusion Criteria:

  1. "Yes" responses for any of the following items on the C-SSRS (within past 6 months):

    • Suicidal Ideation Item 4 (Active Suicidal Ideation with Some Intent to Act, without Specific Plan)
    • Suicidal Ideation Item 5 (Active Suicidal Ideation with Specific Plan and Intent) "Yes" responses for any of the following items on the C-SSRS (within past 2 years):
    • Any of the Suicidal Behavior items (Actual Attempt, Interrupted Attempt, Aborted Attempt, Preparatory Acts or Behavior).

    Serious risk of suicide in the opinion of the investigator is also exclusionary.

  2. Participants shown to carry or be positive for human leukocyte antigen (HLA)-B*1502 or HLA-A*3101.
  3. Use of prohibited medication prior to randomization (5 half-lives) or likely to require prohibited concomitant therapy (e.g., prescription and over-the-counter medications, herbal medications, vitamins, and supplements) during the trial. inhibitors and inducers are prohibited from 30 days prior to signing of the ICF through the end of the trial.
  4. Recent monoamine oxidase inhibitors (MAO-I) use (in the last 28 days) as it increases the risk for and bone marrow suppression from carbamazepine.
  5. Prior carbamazepine use that was discontinued for tolerability or adverse events, including a decrease in , white blood cells or .
  6. Platelets, white blood cell count, or hemoglobin \<lower limit of normal (LLN).
  7. Estimated \<90 milliliters per minute (mL/min)/1.73 m\^2, as calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

NOTE: Other protocol-defined Exclusion criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Tavapadon Followed by Tavapadon + Carbamazepine

    Participants will receive oral tavapadon tablets titrated up to a steady-state dose from Day 1 to Day 14. From Day 15, participants will receive oral carbamazepine tablets titrated up to a steady-state dose along with oral tavapadon tablets, up to Day 30.

    Drug: Tavapadon · Drug: Carbamazepine

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Tavapadon

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 31

  2. Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCτ) of Tavapadon

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 31

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs) and AEs by Severity

    Time frame: Day 1 up to Day 36

  2. Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Values

    Time frame: Up to Day 31

  3. Number of Participants with Clinically Significant Changes in Vital Sign Values

    Time frame: Up to Day 31

  4. Number of Participants with Clinically Significant Changes in Clinical Laboratory Assessments

    Time frame: Up to Day 30

  5. Number of Participants with Clinically Significant Changes in Physical and Neurological Examination Results

    Time frame: Up to Day 31

  6. Changes in Suicidality Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk.

    Time frame: Up to Day 31

07

Study locations

1 site
  • Madison, Wisconsin
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Jan 2023, 3 months.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's 3 months is below that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2022
First posted
Oct 17, 2022
StartActual
Oct 19, 2022
Primary completionActual
Jan 27, 2023
CompletionActual
Feb 2, 2023
Last update
Apr 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05581823
Responsible party
Sponsor
First posted
Oct 17, 2022
Start date
Oct 19, 2022
Primary completion
Jan 27, 2023
Completion
Feb 2, 2023
Last update
Apr 20, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tavapadon

Start the discussion